FB-102
- Generic Name
- FB-102
FibroBiologics Partners with Charles River to Advance Fibroblast-Based Therapy for Diabetic Foot Ulcers
• FibroBiologics has completed a proprietary master cell bank for its fibroblast-based therapy CYWC628, which targets diabetic foot ulcers affecting millions worldwide.
• The company has established a partnership with Charles River Laboratories to manufacture the cell bank and drug products for an upcoming Phase I/II clinical trial scheduled to begin in Q2 2025 in Australia.
• With $14 million in cash reserves and access to additional financing, FibroBiologics aims to complete the clinical trial by the end of 2025, potentially revolutionizing treatment for chronic wounds.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath